The Innovision IPO is a closed mainboard Bookbuilding offer (Fresh Capital & OFS) that opened on 10 March 2026. The Innovision IPO closed on 17 March 2026, with an issue price of ₹519 per share. The Innovision IPO has a face value of ₹10 and a lot size of 27 shares. The Innovision IPO is listed on 17 March 2026. The Innovision IPO allotment was scheduled for 13 March 2026.
On the financial front, the Innovision IPO reported revenue of ₹483 crore for 30 Sep 2025, compared with ₹896 crore for 31 Mar 2025. The Innovision IPO PAT was ₹20 crore against ₹29 crore. The Innovision IPO EBITDA stood at ₹30 crore with a 6.34% margin. The Innovision IPO net worth as of 30 Sep 2025 was ₹102 crore.
Always verify The Innovision IPO details and GMP data with the official offer document before investing in the Innovision IPO.
Financial Summary
Amount in ₹ Crore
Metric
30 Sep 2025
31 Mar 2025
31 Mar 2024
Total Assets
272
220
157
Revenue
483
896
512
PAT
20
29
10
EBITDA
30
52
20
Net Worth
102
82
52
Reserves
83
63
33
Total Borrowing
112
79
48
Innovision IPO Financials FAQs
Revenue of Innovision (Amount in ₹ Crore) — 30 Sep 2025: 483; 31 Mar 2025: 896; 31 Mar 2024: 512. Profit after tax (PAT) — 30 Sep 2025: 20; 31 Mar 2025: 29; 31 Mar 2024: 10.
EBITDA of Innovision (Amount in ₹ Crore) — 30 Sep 2025: 30; 31 Mar 2025: 52; 31 Mar 2024: 20. The EBITDA margin is 6.34%.
Total assets — 30 Sep 2025: 272; 31 Mar 2025: 220; 31 Mar 2024: 157. Net worth — 30 Sep 2025: 102; 31 Mar 2025: 82; 31 Mar 2024: 52. Reserves & surplus — 30 Sep 2025: 83; 31 Mar 2025: 63; 31 Mar 2024: 33. (Amount in ₹ Crore)
Total borrowing of Innovision (Amount in ₹ Crore) — 30 Sep 2025: 112; 31 Mar 2025: 79; 31 Mar 2024: 48. Debt-to-equity ratio: 1.10.
The financials shown for Innovision IPO are taken from the company's offer document (DRHP/RHP/prospectus) filed with the exchange and SEBI, and are updated here when restated figures are published. Always cross-check with the official offer document before investing.
Look at the trend of revenue and PAT across periods, whether EBITDA is growing along with revenue, and whether net worth is rising while borrowings stay under control. The first column may be a part-year (interim) period, so compare full financial years with each other.
GMP and IPO data are unofficial and for information only — not investment advice.
Read the full disclaimer.
